comparemela.com

Latest Breaking News On - Kalyana chakravarti - Page 1 : comparemela.com

How And When To Administer COVID Antibody Cocktail Drug

How And When To Administer COVID Antibody Cocktail Drug Jun 01, 2021, 15:19 IST An 84-year-old man from Haryana became the first person in India to be administered the Covid drug cocktail over a 30 minute intravenous supply and has now been successfully used in various parts of the country. This treatment first came into the limelight after it was administered to former US President Donald Trump when he tested positive for Covid last year. The cocktail drug is a combination of two fast-acting antibodies - Casirivimab and Imdevimab - is seen as a cutting-edge treatment that provides protection to Covid-19 patients with mild and moderate symptoms.

COVID-19: Cocktail antibodies injection used first time in Andhra Pradesh

Covid-19: Cocktail of antibodies injection used first time in Andhra

Read more about Covid-19: Cocktail of antibodies injection used first time in Andhra on Business Standard. Samishta Hospital and Research Institute in Guntur has administered cocktail antibodies injection Regeneron to two patients

COVID-19: Cocktail antibodies injection used first time in Andhra

COVID-19: Cocktail antibodies injection used first time in Andhra ANI | Updated: May 30, 2021 01:57 IST By Pramod Chaturvedi Guntur (Andhra Pradesh) [India], May 29 (ANI): Samishta Hospital and Research Institute (SHRI), Guntur has administered cocktail antibodies injection Regeneron to two patients. This is the first time the cocktail antibodies injection was used in Andhra Pradesh. Dr Kalyana Chakravarti and the team administered the injection. Chakravarti said that both the patients are showing good improvement. He said that patients are recovering well and will soon be discharged. The doctor said that they have stopped using high dose steroids while using Regeneron . Chakravarti further said that they have used stem cell therapy on 12 COVID-19 patients.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.